Current perspective

Development of novel cancer chemopreventive agents in Europe – Neglected Cinderella or rising phoenix?

ESF Workshop on Cancer Chemoprevention, DKFZ, Heidelberg, September 18–20, 2005

Clarissa Gerhausera,*, Helmut Bartscha, James Crowellb, Silvio De Florac, Maurizio D’Incalcid, Christian Dittrichf, Norbert Franka, Enrico Mihichf, Christian Steffeng, Giampaolo Tortorah, Andreas Gescheri,*

a German Cancer Research Center, Toxicology and Cancer Risk Factors, Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
b National Cancer Institute, Division of Cancer Prevention, Bethesda, Maryland, USA
c University of Genoa, Department of Health Sciences, Genoa, Italy
d Istituto di Ricerche Farmacologiche “Mario Negri”, Department of Oncology, Milan, Italy
e Applied Cancer Research-Institution for Translational Research Vienna and LBI-ACR VIEnna, Kaiser Franz Josef Spital, Vienna, Austria
f Roswell Park Cancer Institute, Buffalo, USA
g Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn, Germany
h Università di Napoli “Federico II”, Medical Oncology, Napoli, Italy
i University of Leicester, Department of Cancer Studies, Leicester, UK

ARTICLE INFO

Article history:
Received 26 January 2006
Accepted 10 February 2006
Available online 30 May 2006

Keywords:
Cancer chemoprevention
Experimental animal models
Chemopreventive agents
Biomarkers
Clinical studies
Pharmaceutical industry
RAPID program
Commentary
Europe
European Science Foundation (ESF)
Workshop

ABSTRACT

Agents that prevent cancer, delay its onset, or revert premalignant conditions could have dramatic beneficial impacts on human health. Although there is an urgent need to develop cancer chemopreventive agents, researchers in the field suspect that this area of scientific endeavour in Europe leads a Cinderella existence, both in terms of perception of importance and research funding. In order to review current activities in this prevention field and to seek a consensus position, an exploratory workshop was held in September 2005 at the German Cancer Research Center (DKFZ) in Heidelberg, Germany, sponsored mainly by the European Science Foundation (ESF), and also supported by the European Association for Cancer Research (EACR) and the German Cancer Society (DKG). The 35 experts from European countries and the United States of America assessed state-of-the-art cancer chemoprevention research in Europe. The aims that the workshop organizers had pre-defined were: i) assessment of the usefulness of animal models for agent identification; ii) review of ongoing preclinical and clinical work on novel agents; iii) discussion of potential biomarkers predictive for cancer preventive efficacy; and finally iv) the potential role that European pharmaceutical industries could play in furthering chemopreventive agent development. Overall the workshop aimed at raising awareness among European clinical and laboratory researchers of the importance of the development of novel, efficacious and safe cancer preventive agents.

© 2006 Elsevier Ltd. All rights reserved.

The following text is based on presentations and commentaries given by workshop participants as listed below (page 2):
* Corresponding authors: Tel.: +49 6221423306; fax: +49 6221423359 (C. Gerhauser), Tel.: +44 1162231856; fax: +44 1162231855 (A. Gescher).
E-mail addresses: c.gerhauser@dkfz.de (C. Gerhauser), ag15@leicester.ac.uk (A. Gescher).

0959-8049/$ - see front matter © 2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.ejca.2006.02.007
1. Experimental models of cancer chemoprevention

There are four types of preclinical models used to study mechanisms and efficacy of putative cancer chemopreventive agents: carcinogen-induced rodent models, nude mice bearing transplanted human tumours, genetically modified animals and conditional rodent models. Whereas “classical” chemical-induced models reflect the primary prevention scenario, more recent carcinogenesis models attempt to reproduce clinical conditions that mimic the early phases of tumour development between cellular transformation and the occurrence of small detectable lesions. Experimental models may also establish the extent of parallelism between tumour prevention and modulation of intermediate biomarkers, which can subsequently be validated in clinical trials.

Rodent models are used for the evaluation of mechanism-guided combinations of agents. The nude mouse model harbouring human cancer-derived cells allows hypotheses to be tested resulting from mechanistic experiments in vitro with the same human cell types. As an example, comparative effects of potential prostate cancer chemopreventive agents on levels of prostate-specific antigen (PSA) in both nude mice bearing human prostate tumours and men with prostate cancer permit rapid decisions to be taken as to which agent or food supplement is worthy of further clinical evaluation.1,2 In rodents defective in oncosuppressor genes (p53 or fhit), in which tumours are induced by cigarette smoke and/or UV light, drugs and dietary components have been assayed for their ability to prevent lung tumourigenesis.3 Genomic, transcriptomic, and proteomic changes in the target organ can be probed for as intermediate biomarkers of efficacy.4 The ApcMin mouse model, which develops intestinal adenomas due to a mutated APC gene, allows deductions to be made as to interactions between cancer development (and its inhibition) and oncogenic defect, mimicking conditions underlying human colon carcinogenesis. A provocative meta-analysis of published results of studies on pro- and anti-carcinogenic agents affecting colorectal carcinogenesis in ApcMin mice, azoxymethane-treated rats and in humans has been conducted.5 This comparison suggests that rodent models approximately predict effects in humans and, although not accurate for all agents, they complement each other, providing suitable tools for the development of novel...
agents and exploration of mechanisms. Conditional models of carcinogenesis are research tools, in which oncogenes or defective tumour suppressor genes can be switched on and off.6 Suitably transfected mice allow testing of in vivo mechanistic hypotheses germane to cancer chemoprevention. The consensus view emerged that, given robust hypotheses to be tested, all of these models are useful tools for agent development. A particular advantage of these models is the possibility to study chemopreventive effects on tumour development as well as on host-dependent susceptibility factors such as inflammation or angiogenesis.

2. Preventive agents under development

Several promising putative chemopreventive agents are currently under preclinical investigation in Europe. These include diet-derived phytochemicals, i.e. flavonoids, terpenes, glucosinolates and synthetic agents such as polyethylene glycol (PEG). The broad-spectrum chemopreventive effects of xanthohumol, isolated from hop, are an instructive paradigm.7,8 Short-term animal models, such as the rat uterotrophic model, have been useful in the exploration of its target organ bioavailability and activity. The rice bran-derived flavone tricin delays intestinal carcinogenesis in ApcMin mice.9 Extra-virgin olive oil contains several anti-oxidants in relatively high concentrations,10,11 amongst which the lignan oleocanthal was recently identified and shown to be a potent inhibitor of cyclooxygenase enzymes.12 A diet rich in processed tomato products is associated with a reduced risk of prostate cancer in humans.13 Whether the carotenoid lycopene is the only responsible constituent in tomato remains to be demonstrated. Important for the design of preventive trials is the observation that the anti-oxidant activity of lycopene and other carotenoids is characterized by a U-shaped dose-response curve exhibiting pro-oxidant effects at higher concentrations.14 Isothiocyanates and other anticarcinogenic breakdown products of glucosinolates (sulphur-containing glucosides) are obtained from cruciferous vegetables.15 Regular consumption of Brassica vegetables leads to a cancer risk reduction, especially in carriers of a null polymorphism for the detoxifying enzymes glutathione S-transferases T1 and M1.16 Individuals at increased risk for lung and colorectal cancers may benefit from the protective effects of novel cultivars of broccoli with increased levels of glucosinolates.17 The modulation of gene expression, measured by microarray techniques in the colon epithelium before and after dietary intervention in human and rodents’ colon tissue, may help to identify molecular signatures by dietary components and regimens associated with a reduced colon cancer risk.18,19 Polyethylene glycol (PEG) 8000, used as a laxative, may be a promising synthetic agent for the chemoprevention of experimental colorectal cancer,20 and its efficacy in humans should be verified.

Many putative cancer chemopreventive agents inhibit angiogenesis, blocking the supply of pre-neoplastic and neoplastic tissue with blood and thus retard tumour growth. The “angiopreventive” properties and mechanisms of several agents, including N-acetyl-L-cysteine (NAC), the green tea flavonoid epigallocatechin gallate (EGCG), and synthetic retinoids such as 4-hydroxyphenylretinamide, have been determined in both in vitro and in vivo test systems and through gene expression profiling of endothelial cells.21,22

3. Clinical studies

Pharmaceutical and/or dietary chemopreventive interventions can be applied to asymptomatic healthy individuals (primary prevention), subjects with a premalignant condition (secondary prevention) and patients after cancer therapy (tertiary prevention).23 Phase III clinical trials operate in secondary or tertiary prevention settings. Although the area of clinical cancer chemoprevention trials certainly needs to be strengthened in Europe, there are very interesting clinical activities ongoing in breast cancer chemoprevention. Trials of selective oestrogen receptor modulators (SERMs) like tamoxifen or aromatase inhibitors explore their effect on occurrence or relapse of malignancy in high-risk individuals and in patients.24 Selection of the lowest effective dose of drug to minimize adverse effects is an important issue germane to clinical breast cancer chemoprevention. For instance, studies are addressing the potential to combine hormone replacement therapy or aromatase inhibitors with low doses of anti-estrogens, while higher doses of anti-estrogens are being compared to aromatase inhibitors in women at high risk. The development of preventive agents for hormone-receptor-negative breast cancers remains a challenge. Approaches to lung cancer chemoprevention have turned out to be particularly difficult. The outcome of clinical trials such as the CARET and the ATBC-study using β-carotene or 13-cis-retinoic acid to prevent primary lung tumours or second primary head and neck cancers was negative. Final analyses of the results of these trials emphasized critical issues such as patient selection, mechanistic understanding of the resistance of lung carcinogenesis to retinoids (e.g. involving differential expression and effects of RAR-β isoforms,25), and need for recruitment of sufficiently high numbers of study subjects.26 Phase I/II trials, conducted in parallel with preclinical studies in nude mouse models are used to evaluate phytochemicals and hormone therapy for chemoprevention of prostate cancer. This promising strategy seems particularly suitable for the study of the effect of novel combinations of chemopreventive agents. Such randomized, double-blind, placebo-controlled crossover studies are being conducted in men with prostate cancer and rising PSA.27 Colorectal chemoprevention trials in patients with polyposis depend on the correct selection of the target population to minimize adverse effects and to ensure cost-effectiveness of the intervention.28 In certain circumstances standard colonoscopy and occult blood testing may be more cost-effective than medication with high-dose aspirin (325 mg per day), but the benefits of aspirin on other target systems (e.g. heart disease) may provide an additional advantage. Preclinical and early clinical pilot studies can provide mechanism-based pharmacodynamic and pharmacokinetic parameters that should be exploited to optimize the design of subsequent Phase II/III trials.29 For example, curcumin, a putative colorectal cancer preventive agent derived from Curcuma longa and component of the spice curry, was tested in a pilot study in patients undergoing colectomy.30 Curcumin
levels and pharmacodynamics in the target tissue obtained were measured prior to (biopsies) and post-surgery (surgical specimens).31

Three general issues seem to be important for the implementation of successful clinical prevention trials: i) selection of relevant target populations, either healthy volunteers, individuals at higher cancer risk or cancer patients; ii) definition of measurable disease-relevant end-points and agent-related biomarkers to reflect efficacy; and iii) basing trial design on results obtained in biologically relevant preclinical models.

4. Biomarkers

The development of novel targeted anticancer strategies necessitates identification of surrogate-biomarkers for the early assessment of drug- or nutritional efficacy. Premalignant lesions in the oral cavity and oropharynx are accessible target lesions for prognosis, which can also be exploited as surrogate-endpoint markers for chemopreventive intervention. Genetic analyses with microsatellite markers of cells (brushed samples) of the oral cavity provide high sensitivity and specificity to detect genetic lesions,32 indicating whether a genetic instability is associated with cancer risk. The clinical evaluation of the EGFR-tyrosine kinase inhibitor gefitinib as adjuvant intervention in oral leukoplasia, a pre-malignant condition, was planned in France.33 The trial was halted prematurely by health authorities in 2003, because of the interstitial pneumonia reported to occur in gefitinib-treated Japanese cancer patients.

Minimal invasive procedures together with easy accessibility are being further developed for the early diagnosis of cervical carcinoma. In addition to the classic Papanicolaou smear-test, new optical techniques such as optical coherence tomography and confocal imaging allowing the mapping of subsurface structures are being validated.34,35 Visualization of EGF-receptors with quantum dots conjugated with anti-EGF-receptor antibodies allows detection of changes at the molecular level.36

For assessing efficacy of breast cancer intervention the validation of biomarkers remains an urgent need.37 It is complicated by a number of issues: target populations for intervention studies are difficult to identify; breast tissue is histopathologically very heterogeneous; and proliferation pathways in cells, e.g. cyclin-dependent kinase inhibitors, of toxic side effects and target selective growth controlling might also be used to prevent progression of precancerous lesions to a malignant tumour.42 Intervention trials with such drugs in oral leukoplasia patients are being considered (see Section 4). In addition, chemopreventive phytochemicals that boost the host’s anti-inflammatory defence could sensitize malignant cells to cytotoxic agents and thus should be explored for their usefulness as adjuvants during (or even after) treatment with targeted cancer chemotherapeutic agents, possibly allowing the curative drug dose to be lowered.

5. Role of pharmaceutical industry

Three major reasons explain why the pharmaceutical industry in general has been reluctant to invest in the development of chemopreventive drugs: i) chemoprevention studies last many years and thus proof of efficacy is unlikely to be established before patent expiry; ii) there is a dearth of validated surrogate end-points to measure protective efficacy, the unequivocal end-point being the reduction in cancer death rate, which requires costly long-term studies; iii) the safety profile of a potential chemopreventive agent needs to be rigorously established, as often subjects who are at increased risk of cancer but otherwise healthy, would need to be treated for a long time. This situation requires a most vigorous proof of lack of long-term toxicity, raising the cost of agent development; and iv) many agents proposed for primary chemoprevention cannot be patented; hence the costs of clinical trials cannot be sustained by the industry.40 As to dietary supplements, such as vitamins and trace elements, solid scientific evidence to buttress their marketing as cancer chemopreventive agents is often lacking. In some cases, the available scientific information that would justify the promotion of vitamin C, E, and selenium supplements as cancer preventive agents has been exaggerated for marketing purposes. Moreover, the indiscriminate intake of supplements can cause unwanted side effects, for instance as reported for selenium, which has lead to cases of acute intoxication.41 Until these issues are resolved, the interest of the pharmaceutical industry in this field is likely to remain low. Nevertheless there are promising possibilities in sight: new cancer therapeutic drugs developed by the pharmaceutical industry, which are devoid of toxic side effects and target selective growth controlling pathways in cells, e.g. cyclin-dependent kinase inhibitors, cell surface receptor antibodies and anti-angiogenic agents, might also be used to prevent progression of precancerous lesions to a malignant tumour.42 Intervention trials with such drugs in oral leukoplasia patients are being considered (see Section 4). In addition, chemopreventive phytochemicals that boost the host’s anti-inflammatory defence could sensitize malignant cells to cytotoxic agents and thus should be explored for their usefulness as adjuvants during (or even after) treatment with targeted cancer chemotherapeutic agents, possibly allowing the curative drug dose to be lowered.

6. Cancer chemoprevention agent development in the USA

In the United States the public health agenda of cancer prevention has been advanced to date primarily by academically based researchers with the support of government programs. This effort is centred in the Division of Cancer Prevention of the National Cancer Institute, and this continued commitment over the last two decades has provided a focal point
through which to stimulate this new area of prevention research. Encouragingly, several cancer centres in the USA have now established cancer prevention clinics, the Centre for Scientific Review of the National Institutes of Health has chartered a peer review study section for grant applications in the area of cancer chemoprevention and nutritional intervention, several professional scientific organizations have established meetings, symposia, and journals dedicated to cancer prevention, the NCI and the FDA have established a task force to examine regulatory issues pertaining to cancer prevention, and public advocacy groups have incorporated the message of prevention. Thus, public awareness continues to grow that scientific progress in risk assessment, early detection, and interventions will render some cancers akin to other chronic diseases of aging. In addition, it is important that the Division of Cancer Prevention proactively seeks to engage the international research community and private sector pharmaceutical, food, and nutraceutical industries, and advances the field of cancer prevention by supporting preclinical testing, leading to clinical trials of potential cancer preventive agents. One mechanism is the Rapid Access to Preventive Intervention Development (RAPID) program, which assists academically based investigators to develop novel, potential cancer preventive agents. Based on the peer review process, applications are accepted for applied drug development using the contract resources of the Division of Cancer Prevention. For example, product scale-up or preclinical toxicology studies might be supported. The ultimate intention is to bring a potential preventive drug to a clinical test. All data and technical reports become the property of the applicant; the Division of Cancer Prevention assumes no responsibility. The program is advertised and supported internally and externally.

7. Conclusions and perspectives

Cancer research scientists and physicians recognize that the process of carcinogenesis occurs over decades before manifesting itself clinically. The economic and medical burden of cancer can be reduced by preventing, reversing or delaying this process through dietary, nutritional and lifestyle changes, enhanced screening, and immunological and pharmacological interventions. An impressive amount of high quality work is currently conducted in Europe in the area of experimental and clinical cancer chemoprevention research. A considerable array of novel, diet-derived agents discovered in laboratories across Europe await further testing in rodents and/or in human trials. Promising chemopreventive agents were either detected by extensive in vitro screening in a series of complementary test systems, by epidemiological observations or by serendipitous findings. However, in contrast to the US, where the NCI fosters and coordinates many chemoprevention research and clinical activities, Europe lacks an appropriate coordinating and supporting infrastructure for such activities. This situation seems to be particularly apparent with respect to large clinical trials, the outcome of which could offer great potential health benefits and lower costs for health care of increasingly aging populations. Therefore it seems prudent to suggest that more financial support should be earmarked also in Europe to buttress the development of novel chemopreventive agents, especially their clinical evaluation. EU policy makers should be influenced to boost support for chemoprevention research within EU-framework programs. The urgent need and the rational for developing novel cancer preventive agents and the potential expediency in health political terms derived from their clinical testing, should be propagated and explained to clinicians, practitioners, policy makers and to society at large. Establishing an organization or institutional focal point for cancer chemoprevention research in Europe might be a suitable strategy to facilitate the continued development of this area. The EORTC is one candidate. Such action could help to transform the area of chemoprevention agent development in Europe from a neglected Cinderella to a rising phoenix, shifting emphasis from the cure of end-stage disease to early reversal of carcinogenesis.

Conflict of interest statement

The authors have no financial relationships to disclose.

Acknowledgement

We would like to thank our sponsors for making the workshop possible, and all participants for their valuable contributions.

References
